Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results